COMy 2021 | Can we replace chemotherapy in the myeloma treatment space?
Saad Usmani, MD, University of North Carolina School of Medicine, Chapel Hill, NC, shares his predictions on how the myeloma treatment space will develop in the coming years. Dr Usmani highlights decreasing use of chemotherapy-based regimens in the frontline setting as an exciting possible advancement. Immunotherapy-based approaches, including bispecific antibodies and CAR T-cell therapies, are achieving encouraging results in the relapse setting and may start to be assessed in earlier lines of treatment in the absence of conventional chemotherapy. More investigations are needed to understand if immunotherapeutics alone can improve treatment tolerability and depth of responses. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
Disclosures
Research funding: Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda
Consulting fees: Abbvie, Amgen, BMS, Celgene, GSK, Genentech/Roche, Janssen, Karyopharm, Merck, Oncopeptides, Sanofi, Seattle Genetics, SkylineDx, Takeda
Speaking fees: Celgene, Janssen, Sanofi, Takeda
